Y Jansen1, A A M van der Veldt2, G Awada3, B Neyns3. 1. Department of Surgery UZ Brussel, Laarbeeklaan 101, 1090, Jette, Belgium. Yanina.jansen@gmail.com. 2. Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 3. Department of Oncology UZ Brussel, Laarbeeklaan 101, 1090, Jette, Belgium.
Abstract
PURPOSE OF REVIEW: Emerging data indicate that immune checkpoint blockade (ICB) in patients with metastatic melanoma can be stopped electively or at the time of toxicity with an acceptable risk for progression. However, the optimal treatment duration remains to be defined. We review published data on treatment duration, outcome after treatment discontinuation, and treatment re-introduction in patients with metastatic melanoma. RECENT FINDINGS: Published studies indicate that disease control can be maintained after discontinuation of ICB therapy. Discontinuation of therapy in responders decreases the risk for treatment-related adverse events and lowers the financial burden of ICB. With the limitation of the limited and heterogenous available published data, elective treatment discontinuation after 1 year of treatment appears safe with an acceptable risk of disease progression. The depth of response is currently the best predictor of prolonged response. The metabolic response on 18F-FDG-PET/CT is expected to gain importance, especially for partial responders.
PURPOSE OF REVIEW: Emerging data indicate that immune checkpoint blockade (ICB) in patients with metastatic melanoma can be stopped electively or at the time of toxicity with an acceptable risk for progression. However, the optimal treatment duration remains to be defined. We review published data on treatment duration, outcome after treatment discontinuation, and treatment re-introduction in patients with metastatic melanoma. RECENT FINDINGS: Published studies indicate that disease control can be maintained after discontinuation of ICB therapy. Discontinuation of therapy in responders decreases the risk for treatment-related adverse events and lowers the financial burden of ICB. With the limitation of the limited and heterogenous available published data, elective treatment discontinuation after 1 year of treatment appears safe with an acceptable risk of disease progression. The depth of response is currently the best predictor of prolonged response. The metabolic response on 18F-FDG-PET/CT is expected to gain importance, especially for partial responders.
Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Jacob Schachter; Antoni Ribas; Georgina V Long; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian Blank; Teresa M Petrella; Omid Hamid; Honghong Zhou; Scot Ebbinghaus; Nageatte Ibrahim; Caroline Robert Journal: Lancet Date: 2017-08-16 Impact factor: 79.321
Authors: Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin Journal: Lancet Oncol Date: 2015-03-18 Impact factor: 41.316
Authors: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé Journal: Lancet Oncol Date: 2009-12-08 Impact factor: 41.316
Authors: Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert Journal: JAMA Date: 2016-04-19 Impact factor: 56.272
Authors: Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245
Authors: Antoni Ribas; Igor Puzanov; Reinhard Dummer; Dirk Schadendorf; Omid Hamid; Caroline Robert; F Stephen Hodi; Jacob Schachter; Anna C Pavlick; Karl D Lewis; Lee D Cranmer; Christian U Blank; Steven J O'Day; Paolo A Ascierto; April K S Salama; Kim A Margolin; Carmen Loquai; Thomas K Eigentler; Tara C Gangadhar; Matteo S Carlino; Sanjiv S Agarwala; Stergios J Moschos; Jeffrey A Sosman; Simone M Goldinger; Ronnie Shapira-Frommer; Rene Gonzalez; John M Kirkwood; Jedd D Wolchok; Alexander Eggermont; Xiaoyun Nicole Li; Wei Zhou; Adriane M Zernhelt; Joy Lis; Scot Ebbinghaus; S Peter Kang; Adil Daud Journal: Lancet Oncol Date: 2015-06-23 Impact factor: 41.316
Authors: O Hamid; C Robert; A Daud; F S Hodi; W J Hwu; R Kefford; J D Wolchok; P Hersey; R Joseph; J S Weber; R Dronca; T C Mitchell; A Patnaik; H M Zarour; A M Joshua; Q Zhao; E Jensen; S Ahsan; N Ibrahim; A Ribas Journal: Ann Oncol Date: 2019-04-01 Impact factor: 32.976